Novo Nordisk A\/S (NVO) Recent Earnings
Novo Nordisk A\/S (NVO) reported 3rd Quarter September 2020 earnings of $0.69 per share on revenue of $4.9 billion. The consensus earnings estimate was $0.68 per share on revenue of $4.8 billion. Revenue grew 7.7% on a year-over-year basis.
Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.